EA201290694A1 - Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы - Google Patents
Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназыInfo
- Publication number
- EA201290694A1 EA201290694A1 EA201290694A EA201290694A EA201290694A1 EA 201290694 A1 EA201290694 A1 EA 201290694A1 EA 201290694 A EA201290694 A EA 201290694A EA 201290694 A EA201290694 A EA 201290694A EA 201290694 A1 EA201290694 A1 EA 201290694A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- diarylipyrazoles
- treatment
- sulphonamide derivatives
- proteinkinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Раскрываются соединения, которые являются сульфонамидными производными соединениями 3,4-диарилпиразола, или их фармацевтически приемлемые соли, способ их получения и содержащие их фармацевтические композиции; указанные соединения пригодны для лечения заболеваний, вызываемых и/или связанных с измененной активностью протеинкиназы, таких как рак, вирусная инфекция, для предотвращения развития СПИД у ВИЧ-инфицированных пациентов, для лечения расстройств пролиферации клеток, аутоиммунных и нейродегенеративных расстройств; раскрывается также использование указанных соединений в качестве пролекарств.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151805 | 2010-01-27 | ||
PCT/EP2011/050654 WO2011092088A1 (en) | 2010-01-27 | 2011-01-19 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201290694A1 true EA201290694A1 (ru) | 2013-01-30 |
EA023942B1 EA023942B1 (ru) | 2016-07-29 |
Family
ID=43759815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290694A EA023942B1 (ru) | 2010-01-27 | 2011-01-19 | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы |
Country Status (11)
Country | Link |
---|---|
US (1) | US8791265B2 (ru) |
EP (1) | EP2528909B1 (ru) |
JP (1) | JP5806239B2 (ru) |
KR (1) | KR20120133377A (ru) |
CN (2) | CN104958294A (ru) |
AU (1) | AU2011209234B2 (ru) |
BR (1) | BR112012017705B1 (ru) |
CA (1) | CA2786509C (ru) |
EA (1) | EA023942B1 (ru) |
MX (1) | MX341728B (ru) |
WO (1) | WO2011092088A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009273197B2 (en) * | 2008-07-24 | 2014-01-16 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
JP5938038B2 (ja) | 2010-08-03 | 2016-06-22 | ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ | ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用 |
BR112014011223A8 (pt) | 2011-11-11 | 2023-01-31 | Novartis Ag | Método de tratar uma doença proliferativa |
KR102091295B1 (ko) | 2011-11-23 | 2020-03-19 | 어레이 바이오파마 인크. | 제약 제제 |
DE102011055815A1 (de) * | 2011-11-29 | 2013-05-29 | Aicuris Gmbh & Co. Kg | Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung |
ES2686821T3 (es) | 2013-06-28 | 2018-10-22 | Beigene, Ltd. | Compuestos tricíclicos fusionados de urea como inhibidores de Raf quinasa y/o dímero de Raf quinasa |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1000055A1 (en) | 1997-05-22 | 2000-05-17 | G.D. Searle & Co. | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
ATE374753T1 (de) * | 2001-12-21 | 2007-10-15 | Vernalis Cambridge Ltd | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
EP1917258A2 (en) * | 2005-08-26 | 2008-05-07 | SmithKline Beecham Corporation | Pyrimidinyl-pyrazole inhibitors of aurora kinases |
WO2007105058A2 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
AU2009273197B2 (en) * | 2008-07-24 | 2014-01-16 | Nerviano Medical Sciences S.R.L. | 3,4-diarylpyrazoles as protein kinase inhibitors |
-
2011
- 2011-01-19 MX MX2012008445A patent/MX341728B/es active IP Right Grant
- 2011-01-19 EP EP11701381.3A patent/EP2528909B1/en not_active Not-in-force
- 2011-01-19 WO PCT/EP2011/050654 patent/WO2011092088A1/en active Application Filing
- 2011-01-19 AU AU2011209234A patent/AU2011209234B2/en active Active
- 2011-01-19 CA CA2786509A patent/CA2786509C/en active Active
- 2011-01-19 US US13/574,168 patent/US8791265B2/en active Active
- 2011-01-19 CN CN201510202938.6A patent/CN104958294A/zh active Pending
- 2011-01-19 JP JP2012550391A patent/JP5806239B2/ja active Active
- 2011-01-19 EA EA201290694A patent/EA023942B1/ru unknown
- 2011-01-19 KR KR1020127020798A patent/KR20120133377A/ko not_active Application Discontinuation
- 2011-01-19 CN CN201180017070.2A patent/CN102947290B/zh active Active
- 2011-01-19 BR BR112012017705-2A patent/BR112012017705B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2528909A1 (en) | 2012-12-05 |
JP2013518071A (ja) | 2013-05-20 |
CN104958294A (zh) | 2015-10-07 |
CN102947290A (zh) | 2013-02-27 |
MX2012008445A (es) | 2012-11-12 |
KR20120133377A (ko) | 2012-12-10 |
JP5806239B2 (ja) | 2015-11-10 |
CA2786509C (en) | 2016-01-05 |
US8791265B2 (en) | 2014-07-29 |
AU2011209234B2 (en) | 2015-05-07 |
BR112012017705A2 (pt) | 2016-04-05 |
EA023942B1 (ru) | 2016-07-29 |
US20130053419A1 (en) | 2013-02-28 |
BR112012017705B1 (pt) | 2020-03-24 |
AU2011209234A1 (en) | 2012-07-26 |
EP2528909B1 (en) | 2016-06-22 |
WO2011092088A1 (en) | 2011-08-04 |
CN102947290B (zh) | 2015-05-27 |
CA2786509A1 (en) | 2011-08-04 |
MX341728B (es) | 2016-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы | |
EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
EA201492082A1 (ru) | Кристаллические формы ингибитора тирозинкиназы брутона | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
EA201391752A1 (ru) | Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2 | |
EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
EA201201680A1 (ru) | Морфолинопиримидины и их применение в терапии | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
EA201490696A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh | |
EA202090258A3 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
UA111770C2 (uk) | Інгібітори бромдомену | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
EA201491321A1 (ru) | Фторметил-5,6-дигидро-4н-[1,3]оксазины | |
MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
EA201600337A1 (ru) | 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний | |
EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии |